PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
31696375-9	2020	Atorvastatin reversed all these alterations in parallel with a decrease in circulating levels of cytokines (IL-1beta, IL-4, IL-6, and TNF-alpha) in plasma, inhibited the activities of oxidative stress parameters (lower TBARS levels, ratio of GSH/GSSH, and activities of SOD and CAT), enhanced the activity of citrate synthase in brain, and reduced the number of astrocytes and neuronal cell deaths in CA3 region of hippocampus.	atorvastatin	0-12	interleukin 1 beta	Mus musculus	108-116
31564240-12	2020	In addition, recombinant human granulocyte colony-stimulating factor + stromal cell-derived factor-1 promoted greater angiogenesis than atorvastatin or recombinant human granulocyte colony-stimulating factor alone and increased the expression of growth-associated protein-43, neuroglobin, and glial cell-derived neurotrophic factor, while decreasing the levels of cleaved caspase 3 in the brain after ischemic stroke.	atorvastatin	136-148	colony stimulating factor 3	Homo sapiens	31-68
31564240-12	2020	In addition, recombinant human granulocyte colony-stimulating factor + stromal cell-derived factor-1 promoted greater angiogenesis than atorvastatin or recombinant human granulocyte colony-stimulating factor alone and increased the expression of growth-associated protein-43, neuroglobin, and glial cell-derived neurotrophic factor, while decreasing the levels of cleaved caspase 3 in the brain after ischemic stroke.	atorvastatin	136-148	C-X-C motif chemokine ligand 12	Homo sapiens	71-100
31564240-13	2020	CONCLUSIONS: Combination therapy with recombinant human granulocyte colony-stimulating factor and stromal cell-derived factor-1 is more effective than atorvastatin or recombinant human granulocyte colony-stimulating factor alone in protecting against stroke-induced damage and could be an optimal therapeutic strategy for stroke.	atorvastatin	151-163	colony stimulating factor 3	Homo sapiens	56-93
31696375-9	2020	Atorvastatin reversed all these alterations in parallel with a decrease in circulating levels of cytokines (IL-1beta, IL-4, IL-6, and TNF-alpha) in plasma, inhibited the activities of oxidative stress parameters (lower TBARS levels, ratio of GSH/GSSH, and activities of SOD and CAT), enhanced the activity of citrate synthase in brain, and reduced the number of astrocytes and neuronal cell deaths in CA3 region of hippocampus.	atorvastatin	0-12	interleukin 4	Mus musculus	118-122
31696375-9	2020	Atorvastatin reversed all these alterations in parallel with a decrease in circulating levels of cytokines (IL-1beta, IL-4, IL-6, and TNF-alpha) in plasma, inhibited the activities of oxidative stress parameters (lower TBARS levels, ratio of GSH/GSSH, and activities of SOD and CAT), enhanced the activity of citrate synthase in brain, and reduced the number of astrocytes and neuronal cell deaths in CA3 region of hippocampus.	atorvastatin	0-12	interleukin 6	Mus musculus	124-128
31696375-9	2020	Atorvastatin reversed all these alterations in parallel with a decrease in circulating levels of cytokines (IL-1beta, IL-4, IL-6, and TNF-alpha) in plasma, inhibited the activities of oxidative stress parameters (lower TBARS levels, ratio of GSH/GSSH, and activities of SOD and CAT), enhanced the activity of citrate synthase in brain, and reduced the number of astrocytes and neuronal cell deaths in CA3 region of hippocampus.	atorvastatin	0-12	tumor necrosis factor	Mus musculus	134-143
31696375-9	2020	Atorvastatin reversed all these alterations in parallel with a decrease in circulating levels of cytokines (IL-1beta, IL-4, IL-6, and TNF-alpha) in plasma, inhibited the activities of oxidative stress parameters (lower TBARS levels, ratio of GSH/GSSH, and activities of SOD and CAT), enhanced the activity of citrate synthase in brain, and reduced the number of astrocytes and neuronal cell deaths in CA3 region of hippocampus.	atorvastatin	0-12	catalase	Mus musculus	278-281
31911428-9	2020	Nuclear activity of FXR was reduced by atorvastatin in a mouse FXR reporter assay.	atorvastatin	39-51	nuclear receptor subfamily 1, group H, member 4	Mus musculus	20-23
31897532-2	2020	The aim of the study was to evaluate the effect of genetic polymorphisms of ABCB1 and the selected cytochrome P450 isoenzymes on the pharmacodynamics and pharmacokinetics of CLP and its metabolites in patients co-treated with atorvastatin or rosuvastatin.	atorvastatin	226-238	ATP binding cassette subfamily B member 1	Homo sapiens	76-81
31897532-9	2020	In the atorvastatin group, CYP2C19*2, CYP3A4*1G, and ABCB1 C3435T TT genotypes were independent determinants of PRU values (P < 0.01).	atorvastatin	7-19	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	27-34
31897532-9	2020	In the atorvastatin group, CYP2C19*2, CYP3A4*1G, and ABCB1 C3435T TT genotypes were independent determinants of PRU values (P < 0.01).	atorvastatin	7-19	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	38-44
31897532-9	2020	In the atorvastatin group, CYP2C19*2, CYP3A4*1G, and ABCB1 C3435T TT genotypes were independent determinants of PRU values (P < 0.01).	atorvastatin	7-19	ATP binding cassette subfamily B member 1	Homo sapiens	53-58
31897532-10	2020	CONCLUSION: The CYP2C19*2 allele is the primary determinant of the exposition to the H4 active metabolite of clopidogrel and platelet reactivity in patients co-treated with atorvastatin or rosuvastatin.	atorvastatin	173-185	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	16-23
32051095-0	2020	Atorvastatin inhibits IL-17A, TNF, IL-6, and IL-10 in PBMC cultures from patients with severe rheumatoid arthritis.	atorvastatin	0-12	interleukin 17A	Homo sapiens	22-28
32051095-0	2020	Atorvastatin inhibits IL-17A, TNF, IL-6, and IL-10 in PBMC cultures from patients with severe rheumatoid arthritis.	atorvastatin	0-12	tumor necrosis factor	Homo sapiens	30-33
32051095-0	2020	Atorvastatin inhibits IL-17A, TNF, IL-6, and IL-10 in PBMC cultures from patients with severe rheumatoid arthritis.	atorvastatin	0-12	interleukin 6	Homo sapiens	35-39
32051095-0	2020	Atorvastatin inhibits IL-17A, TNF, IL-6, and IL-10 in PBMC cultures from patients with severe rheumatoid arthritis.	atorvastatin	0-12	interleukin 10	Homo sapiens	45-50
32051095-10	2020	RESULTS: Atorvastatin showed no toxicity at the tested doses in RA PBMC cultures, and at 10muM, it showed the most significant results, reducing IL-17A (p = 0.002), TNF (p = 0.002), and IL-6 (p = 0.008) supernatant levels.	atorvastatin	9-21	interleukin 17A	Homo sapiens	145-151
32051095-10	2020	RESULTS: Atorvastatin showed no toxicity at the tested doses in RA PBMC cultures, and at 10muM, it showed the most significant results, reducing IL-17A (p = 0.002), TNF (p = 0.002), and IL-6 (p = 0.008) supernatant levels.	atorvastatin	9-21	tumor necrosis factor	Homo sapiens	165-168
32051095-10	2020	RESULTS: Atorvastatin showed no toxicity at the tested doses in RA PBMC cultures, and at 10muM, it showed the most significant results, reducing IL-17A (p = 0.002), TNF (p = 0.002), and IL-6 (p = 0.008) supernatant levels.	atorvastatin	9-21	interleukin 6	Homo sapiens	186-190
32004772-1	2020	Fluvastatin and atorvastatin are inhibitors of hydroxy-methylglutaryl-CoA (HMG-CoA) reductase, the enzyme that converts HMG-CoA to mevalonic acid (MVA).	atorvastatin	16-28	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	75-93
31911428-9	2020	Nuclear activity of FXR was reduced by atorvastatin in a mouse FXR reporter assay.	atorvastatin	39-51	nuclear receptor subfamily 1, group H, member 4	Mus musculus	63-66
31911428-10	2020	The atorvastatin-induced decrease in insulin release was also present in FXR-KO mice.	atorvastatin	4-16	nuclear receptor subfamily 1, group H, member 4	Mus musculus	73-76
31911428-11	2020	Though not a prerequisite, FXR seems to influence the degree of damage caused by atorvastatin in dependence of its interaction with CDC: Preparations responding to CDC with an increase in insulin secretion under control conditions were less impaired by atorvastatin than preparations that were non-responsive to CDC.	atorvastatin	81-93	nuclear receptor subfamily 1, group H, member 4	Mus musculus	27-30
31911428-12	2020	Extended stimulation of FXR by the synthetic agonist GW4064, which is suggested to induce translocation of FXR from the cytosol into the nucleus, increased the inhibitory effect of atorvastatin.	atorvastatin	181-193	nuclear receptor subfamily 1, group H, member 4	Mus musculus	24-27
31911428-12	2020	Extended stimulation of FXR by the synthetic agonist GW4064, which is suggested to induce translocation of FXR from the cytosol into the nucleus, increased the inhibitory effect of atorvastatin.	atorvastatin	181-193	nuclear receptor subfamily 1, group H, member 4	Mus musculus	107-110
32047080-4	2020	Nifedipine (a weak inhibitor of CYP3A4 and competing substrate) and clopidogrel (a competitive inhibitor of CYP3A4) may have affected the metabolism of atorvastatin, resulting in the elevation of serum alkaline phosphatase levels to over six times the upper limit of normal.	atorvastatin	152-164	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	32-38
32047080-4	2020	Nifedipine (a weak inhibitor of CYP3A4 and competing substrate) and clopidogrel (a competitive inhibitor of CYP3A4) may have affected the metabolism of atorvastatin, resulting in the elevation of serum alkaline phosphatase levels to over six times the upper limit of normal.	atorvastatin	152-164	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	108-114
31901240-0	2020	Beneficial effect of ezetimibe-atorvastatin combination therapy in patients with a mutation in ABCG5 or ABCG8 gene.	atorvastatin	21-43	ATP binding cassette subfamily G member 5	Homo sapiens	95-100
31955966-9	2020	Combining 13 effect sizes from 10 studies, a significant reduction in serum CRP concentration following the administration of atorvastatin was found (WMD, -0.35; 95% CI, -0.54 to -0.17; I2 = 90.6%).	atorvastatin	126-138	C-reactive protein	Homo sapiens	76-79
31955966-10	2020	Based on 5 effect sizes from 4 studies, we found a statistically significant reduction in serum IL-6 concentration after atorvastatin therapy (WMD, -0.44; 95% CI, -0.65 to -0.22; I2 = 93.9%).	atorvastatin	121-133	interleukin 6	Homo sapiens	96-100
31955966-12	2020	IMPLICATIONS: The administration of atorvastatin or simvastatin in patients with abnormal glucose hemostasis was associated with a reduced serum CRP concentration.	atorvastatin	36-48	C-reactive protein	Homo sapiens	145-148
31955966-13	2020	Atorvastatin therapy might also help to decrease serum IL-6 concentration in these patients.	atorvastatin	0-12	interleukin 6	Homo sapiens	55-59
31901240-0	2020	Beneficial effect of ezetimibe-atorvastatin combination therapy in patients with a mutation in ABCG5 or ABCG8 gene.	atorvastatin	21-43	ATP binding cassette subfamily G member 8	Homo sapiens	104-109
31901240-12	2020	CONCLUSION: These results suggest that ezetimibe-atorvastatin combination therapy might be more beneficial in hypercholesterolemic patients with a mutation in ABCG5 or ABCG8 gene.	atorvastatin	39-61	ATP binding cassette subfamily G member 5	Homo sapiens	159-164
31901240-12	2020	CONCLUSION: These results suggest that ezetimibe-atorvastatin combination therapy might be more beneficial in hypercholesterolemic patients with a mutation in ABCG5 or ABCG8 gene.	atorvastatin	39-61	ATP binding cassette subfamily G member 8	Homo sapiens	168-173
31830726-0	2020	Atorvastatin inhibits pyroptosis through the lncRNA NEXN-AS1/NEXN pathway in human vascular endothelial cells.	atorvastatin	0-12	NEXN antisense RNA 1	Homo sapiens	52-60
31830726-0	2020	Atorvastatin inhibits pyroptosis through the lncRNA NEXN-AS1/NEXN pathway in human vascular endothelial cells.	atorvastatin	0-12	nexilin F-actin binding protein	Homo sapiens	52-56
31830726-6	2020	The promotion effects of atorvastatin on NEXN-AS1 and NEXN expression could be significantly abolished by knockdown of lncRNA NEXN-AS1 or NEXN, and its inhibitory effects on pyroptosis were also markedly offset by knock-down of lncRNA NEXN-AS1 or interference of NEXN.	atorvastatin	25-37	nexilin F-actin binding protein	Homo sapiens	54-58
31830726-6	2020	The promotion effects of atorvastatin on NEXN-AS1 and NEXN expression could be significantly abolished by knockdown of lncRNA NEXN-AS1 or NEXN, and its inhibitory effects on pyroptosis were also markedly offset by knock-down of lncRNA NEXN-AS1 or interference of NEXN.	atorvastatin	25-37	NEXN antisense RNA 1	Homo sapiens	126-134
31830726-4	2020	RESULTS: Atorvastatin upregulated long non-coding RNA (lncRNA) NEXN-AS1 and the expression of NEXN at both the mRNA and protein levels in a concentration- and time-dependent manner.	atorvastatin	9-21	NEXN antisense RNA 1	Homo sapiens	63-71
31830726-6	2020	The promotion effects of atorvastatin on NEXN-AS1 and NEXN expression could be significantly abolished by knockdown of lncRNA NEXN-AS1 or NEXN, and its inhibitory effects on pyroptosis were also markedly offset by knock-down of lncRNA NEXN-AS1 or interference of NEXN.	atorvastatin	25-37	nexilin F-actin binding protein	Homo sapiens	54-58
31830726-4	2020	RESULTS: Atorvastatin upregulated long non-coding RNA (lncRNA) NEXN-AS1 and the expression of NEXN at both the mRNA and protein levels in a concentration- and time-dependent manner.	atorvastatin	9-21	nexilin F-actin binding protein	Homo sapiens	63-67
31830726-7	2020	CONCLUSIONS: These results demonstrated that atorvastatin regulated pyroptosis via the lncRNA NEXN-AS1-NEXN pathway, which provides a new insight into the mechanism of how atorvastatin promotes non-lipid-lower effects against the development of atherosclerosis and gives new directions on how to reverse atherosclerosis.	atorvastatin	45-57	NEXN antisense RNA 1	Homo sapiens	94-102
31830726-5	2020	Atorvastatin inhibited pyroptosis by decreasing the expression levels of the canonical inflammasome pathway biomarkers NLRP3, caspase-1, GSDMD, IL-1beta, and IL-18 at both the mRNA and protein levels.	atorvastatin	0-12	NLR family pyrin domain containing 3	Homo sapiens	119-124
31830726-7	2020	CONCLUSIONS: These results demonstrated that atorvastatin regulated pyroptosis via the lncRNA NEXN-AS1-NEXN pathway, which provides a new insight into the mechanism of how atorvastatin promotes non-lipid-lower effects against the development of atherosclerosis and gives new directions on how to reverse atherosclerosis.	atorvastatin	45-57	nexilin F-actin binding protein	Homo sapiens	94-98
31830726-7	2020	CONCLUSIONS: These results demonstrated that atorvastatin regulated pyroptosis via the lncRNA NEXN-AS1-NEXN pathway, which provides a new insight into the mechanism of how atorvastatin promotes non-lipid-lower effects against the development of atherosclerosis and gives new directions on how to reverse atherosclerosis.	atorvastatin	172-184	NEXN antisense RNA 1	Homo sapiens	94-102
31830726-7	2020	CONCLUSIONS: These results demonstrated that atorvastatin regulated pyroptosis via the lncRNA NEXN-AS1-NEXN pathway, which provides a new insight into the mechanism of how atorvastatin promotes non-lipid-lower effects against the development of atherosclerosis and gives new directions on how to reverse atherosclerosis.	atorvastatin	172-184	nexilin F-actin binding protein	Homo sapiens	94-98
31830726-5	2020	Atorvastatin inhibited pyroptosis by decreasing the expression levels of the canonical inflammasome pathway biomarkers NLRP3, caspase-1, GSDMD, IL-1beta, and IL-18 at both the mRNA and protein levels.	atorvastatin	0-12	caspase 1	Homo sapiens	126-135
31830726-5	2020	Atorvastatin inhibited pyroptosis by decreasing the expression levels of the canonical inflammasome pathway biomarkers NLRP3, caspase-1, GSDMD, IL-1beta, and IL-18 at both the mRNA and protein levels.	atorvastatin	0-12	gasdermin D	Homo sapiens	137-142
31830726-5	2020	Atorvastatin inhibited pyroptosis by decreasing the expression levels of the canonical inflammasome pathway biomarkers NLRP3, caspase-1, GSDMD, IL-1beta, and IL-18 at both the mRNA and protein levels.	atorvastatin	0-12	interleukin 1 beta	Homo sapiens	144-152
31830726-5	2020	Atorvastatin inhibited pyroptosis by decreasing the expression levels of the canonical inflammasome pathway biomarkers NLRP3, caspase-1, GSDMD, IL-1beta, and IL-18 at both the mRNA and protein levels.	atorvastatin	0-12	interleukin 18	Homo sapiens	158-163
31830726-6	2020	The promotion effects of atorvastatin on NEXN-AS1 and NEXN expression could be significantly abolished by knockdown of lncRNA NEXN-AS1 or NEXN, and its inhibitory effects on pyroptosis were also markedly offset by knock-down of lncRNA NEXN-AS1 or interference of NEXN.	atorvastatin	25-37	NEXN antisense RNA 1	Homo sapiens	41-49
31830726-6	2020	The promotion effects of atorvastatin on NEXN-AS1 and NEXN expression could be significantly abolished by knockdown of lncRNA NEXN-AS1 or NEXN, and its inhibitory effects on pyroptosis were also markedly offset by knock-down of lncRNA NEXN-AS1 or interference of NEXN.	atorvastatin	25-37	nexilin F-actin binding protein	Homo sapiens	41-45
31830726-6	2020	The promotion effects of atorvastatin on NEXN-AS1 and NEXN expression could be significantly abolished by knockdown of lncRNA NEXN-AS1 or NEXN, and its inhibitory effects on pyroptosis were also markedly offset by knock-down of lncRNA NEXN-AS1 or interference of NEXN.	atorvastatin	25-37	NEXN antisense RNA 1	Homo sapiens	126-134
31865360-0	2019	Oxidized Low Density Lipoprotein-Induced Atherogenic Response of Human Umbilical Vascular Endothelial Cells (HUVECs) was Protected by Atorvastatin by Regulating miR-26a-5p/Phosphatase and Tensin Homolog (PTEN).	atorvastatin	134-146	phosphatase and tensin homolog	Homo sapiens	204-208
31656041-7	2020	Clinical factors associated with ATV and/or its metabolite levels included age, sex, body mass index, and CYP3A inhibiting co-medications.	atorvastatin	33-36	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	106-111
31656041-10	2020	An interaction between PPIs and CYP2C19 metaboliser status on exposure to specific ATV analytes (e.g. interaction p=0.0071 for 2-OH ATV L) was observed.	atorvastatin	83-86	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	32-39
31656041-10	2020	An interaction between PPIs and CYP2C19 metaboliser status on exposure to specific ATV analytes (e.g. interaction p=0.0071 for 2-OH ATV L) was observed.	atorvastatin	132-135	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	32-39
31866378-0	2020	Atorvastatin protects cardiomyocyte from doxorubicin toxicity by modulating survivin expression through FOXO1 inhibition.	atorvastatin	0-12	baculoviral IAP repeat-containing 5	Mus musculus	76-84
31866378-0	2020	Atorvastatin protects cardiomyocyte from doxorubicin toxicity by modulating survivin expression through FOXO1 inhibition.	atorvastatin	0-12	forkhead box O1	Mus musculus	104-109
31866378-7	2020	Whereas, atorvastatin inhibited FOXO1 by increasing phosphorylation and inhibiting nuclear localization.	atorvastatin	9-21	forkhead box O1	Mus musculus	32-37
31866378-9	2020	However, atorvastatin inhibited these interactions and stabilized STAT3/Sp1 transcription complex.	atorvastatin	9-21	signal transducer and activator of transcription 3	Mus musculus	66-71
31866378-11	2020	In mouse model, atorvastatin rescued doxorubicin-induced reduction of survivin expression and of heart function measured by cardiac magnetic resonance imaging.	atorvastatin	16-28	baculoviral IAP repeat-containing 5	Mus musculus	70-78
31866378-12	2020	CONCLUSIONS: Our study suggested a new pathophysiologic mechanism that survivin mediated protective effect of atorvastatin against doxorubicin-induced cardiotoxicity via FOXO1/STAT3/Sp1 transcriptional network.	atorvastatin	110-122	baculoviral IAP repeat-containing 5	Mus musculus	71-79
31866378-12	2020	CONCLUSIONS: Our study suggested a new pathophysiologic mechanism that survivin mediated protective effect of atorvastatin against doxorubicin-induced cardiotoxicity via FOXO1/STAT3/Sp1 transcriptional network.	atorvastatin	110-122	signal transducer and activator of transcription 3	Mus musculus	176-181
31865360-10	2019	CONCLUSIONS Our results highlight that ATV protects against ox-LDL-induced downregulation of cell viability, upregulation of cell apoptosis, migration, as well as the release of adhesion-related molecules in HUVECs through the miR-26a-5p/PTEN axis.	atorvastatin	39-42	phosphatase and tensin homolog	Homo sapiens	238-242
31841211-0	2019	Effect of atorvastatin on pulmonary arterial hypertension in rats through PI3K/AKT signaling pathway.	atorvastatin	10-22	AKT serine/threonine kinase 1	Rattus norvegicus	79-82
31841211-1	2019	OBJECTIVE: The aim of this study was to investigate the effect of atorvastatin on pulmonary arterial hypertension (PAH) in rats and to observe its specific regulatory mechanism through the phosphatidylinositol 3-hydroxy kinase/protein kinase B (PI3K/AKT) signaling pathway.	atorvastatin	66-78	AKT serine/threonine kinase 1	Rattus norvegicus	250-253
31841211-16	2019	All the above results indicated that atorvastatin could effectively up-regulate the expressions of PI3K and AKT (p<0.05).	atorvastatin	37-49	phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma	Rattus norvegicus	99-111
31841211-17	2019	CONCLUSIONS: Atorvastatin regulates the symptoms of PAH in rats through activating the PI3K/AKT signaling pathway.	atorvastatin	13-25	AKT serine/threonine kinase 1	Rattus norvegicus	92-95
31828139-7	2019	Atorvastatin therapy attenuated dyslipidaemia, renal insufficiency, reduced hepatic lipids, HMG-CoA reductase and ACAT2 protein abundance and raised LDL receptor and lipase protein expression.	atorvastatin	0-12	sterol O-acyltransferase 2	Rattus norvegicus	114-119
32048627-8	2019	Inhibitor concentration 50 (IC50) values calculated for atorvastatin and simvastatin were determined as 94 and 38 muM, respectively.	atorvastatin	56-68	latexin	Homo sapiens	114-117
32048627-10	2019	When six concentrations of bortezomib used in the study were combined with 12.5 muM inactive concentrations of statins that did not cause inhibition in cell proliferation, both atorvastatin and simvastatin increased the effect of bortezomib at all the concentrations used, and simvastatin showed a stronger efficacy than atorvastatin.	atorvastatin	177-189	latexin	Homo sapiens	80-83
31781960-10	2019	We demonstrate in pigs and rodents that prompt intravenous treatment with atorvastatin during ischemia limits cardiac cell death and reduces infarct size through AMPK signaling.	atorvastatin	74-86	protein kinase AMP-activated catalytic subunit alpha 1	Sus scrofa	162-166
31780674-4	2019	Here we show that endosomal localization of Rab-GTPases (Rab5, Rab7 and Rab11) was inhibited in a statin-specific manner, with stronger effects by fluvastatin, followed by simvastatin and atorvastatin, and with a limited effect by rosuvastatin.	atorvastatin	188-200	RAB5A, member RAS oncogene family	Homo sapiens	57-61
31780674-4	2019	Here we show that endosomal localization of Rab-GTPases (Rab5, Rab7 and Rab11) was inhibited in a statin-specific manner, with stronger effects by fluvastatin, followed by simvastatin and atorvastatin, and with a limited effect by rosuvastatin.	atorvastatin	188-200	RAB7B, member RAS oncogene family	Homo sapiens	63-67
31780674-4	2019	Here we show that endosomal localization of Rab-GTPases (Rab5, Rab7 and Rab11) was inhibited in a statin-specific manner, with stronger effects by fluvastatin, followed by simvastatin and atorvastatin, and with a limited effect by rosuvastatin.	atorvastatin	188-200	RAB11A, member RAS oncogene family	Homo sapiens	72-77
31697643-6	2019	The proteome data revealed that atorvastatin inhibited the cAMP and Rap1 signal pathways, except for Ras signal pathway.	atorvastatin	32-44	RAP1A, member of RAS oncogene family	Homo sapiens	68-72
31852645-0	2019	[Effect of atorvastatin on LOX-1 and eNOS expression in collateral vessels of hypercholesterolemic rats].	atorvastatin	11-23	oxidized low density lipoprotein receptor 1	Rattus norvegicus	27-32
31852645-0	2019	[Effect of atorvastatin on LOX-1 and eNOS expression in collateral vessels of hypercholesterolemic rats].	atorvastatin	11-23	nitric oxide synthase 3	Rattus norvegicus	37-41
31852645-1	2019	OBJECTIVE: To investigate the effect of atorvastatin on the expression of lectin- like oxLDL receptor 1 (LOX-1) and endothelial nitric oxide synthase (eNOS) in collateral vessels of hypercholesterolemic rats.	atorvastatin	40-52	oxidized low density lipoprotein receptor 1	Rattus norvegicus	74-103
31852645-1	2019	OBJECTIVE: To investigate the effect of atorvastatin on the expression of lectin- like oxLDL receptor 1 (LOX-1) and endothelial nitric oxide synthase (eNOS) in collateral vessels of hypercholesterolemic rats.	atorvastatin	40-52	oxidized low density lipoprotein receptor 1	Rattus norvegicus	105-110
31852645-1	2019	OBJECTIVE: To investigate the effect of atorvastatin on the expression of lectin- like oxLDL receptor 1 (LOX-1) and endothelial nitric oxide synthase (eNOS) in collateral vessels of hypercholesterolemic rats.	atorvastatin	40-52	nitric oxide synthase 3	Rattus norvegicus	116-149
31852645-1	2019	OBJECTIVE: To investigate the effect of atorvastatin on the expression of lectin- like oxLDL receptor 1 (LOX-1) and endothelial nitric oxide synthase (eNOS) in collateral vessels of hypercholesterolemic rats.	atorvastatin	40-52	nitric oxide synthase 3	Rattus norvegicus	151-155
31852645-8	2019	RESULTS: The collateral vessels of rats with normal feeding expressed LOX-1, which was significantly increased in the collateral vessels of hypercholesterolemic rats; atorvastatin treatment significantly lowered LOX-1 expressions in the hypercholesterolemic rats.	atorvastatin	167-179	oxidized low density lipoprotein receptor 1	Rattus norvegicus	70-75
31852645-8	2019	RESULTS: The collateral vessels of rats with normal feeding expressed LOX-1, which was significantly increased in the collateral vessels of hypercholesterolemic rats; atorvastatin treatment significantly lowered LOX-1 expressions in the hypercholesterolemic rats.	atorvastatin	167-179	oxidized low density lipoprotein receptor 1	Rattus norvegicus	212-217
31852645-9	2019	In normally fed rats, the growing collateral vessels exhibited strong eNOS expressions, which were lowered in hypercholesterolemic rats and enhanced after atorvastatin treatment.	atorvastatin	155-167	nitric oxide synthase 3	Rattus norvegicus	70-74
31852645-10	2019	In the cell experiment, HUVECs with oxLDL treatment showed a high LOX-1 expression and a low eNOS expression, and atorvastatin treatment of the cells down-regulated LOX-1 and up-regulated eNOS expressions.	atorvastatin	114-126	oxidized low density lipoprotein receptor 1	Rattus norvegicus	165-170
31852645-10	2019	In the cell experiment, HUVECs with oxLDL treatment showed a high LOX-1 expression and a low eNOS expression, and atorvastatin treatment of the cells down-regulated LOX-1 and up-regulated eNOS expressions.	atorvastatin	114-126	nitric oxide synthase 3	Rattus norvegicus	188-192
31852645-12	2019	CONCLUSIONS: Both hypercholesterolemia and oxLDL can induce endothelial dysfunction and impair collateral vessel growth via the LOX-1/eNOS pathway in rats, and atorvastatin treatment can restore the LOX-1/eNOS pathway to promote the growth of the collateral vessels, suggesting the potential of atorvastatin as a therapeutic agent to promote repair of collateral vessel injuries in ischemic diseases.	atorvastatin	160-172	oxidized low density lipoprotein receptor 1	Rattus norvegicus	128-133
31852645-12	2019	CONCLUSIONS: Both hypercholesterolemia and oxLDL can induce endothelial dysfunction and impair collateral vessel growth via the LOX-1/eNOS pathway in rats, and atorvastatin treatment can restore the LOX-1/eNOS pathway to promote the growth of the collateral vessels, suggesting the potential of atorvastatin as a therapeutic agent to promote repair of collateral vessel injuries in ischemic diseases.	atorvastatin	160-172	oxidized low density lipoprotein receptor 1	Rattus norvegicus	199-204
31852645-12	2019	CONCLUSIONS: Both hypercholesterolemia and oxLDL can induce endothelial dysfunction and impair collateral vessel growth via the LOX-1/eNOS pathway in rats, and atorvastatin treatment can restore the LOX-1/eNOS pathway to promote the growth of the collateral vessels, suggesting the potential of atorvastatin as a therapeutic agent to promote repair of collateral vessel injuries in ischemic diseases.	atorvastatin	160-172	nitric oxide synthase 3	Rattus norvegicus	205-209
31828139-7	2019	Atorvastatin therapy attenuated dyslipidaemia, renal insufficiency, reduced hepatic lipids, HMG-CoA reductase and ACAT2 protein abundance and raised LDL receptor and lipase protein expression.	atorvastatin	0-12	low density lipoprotein receptor	Rattus norvegicus	149-161
31828139-7	2019	Atorvastatin therapy attenuated dyslipidaemia, renal insufficiency, reduced hepatic lipids, HMG-CoA reductase and ACAT2 protein abundance and raised LDL receptor and lipase protein expression.	atorvastatin	0-12	lipase G, endothelial type	Rattus norvegicus	166-172
31828139-8	2019	Atorvastatin therapy decreased the enzymatic activity of HMG-CoA reductase and increased enzymatic activity of lipase and LCAT.	atorvastatin	0-12	lipase G, endothelial type	Rattus norvegicus	111-117
31828139-8	2019	Atorvastatin therapy decreased the enzymatic activity of HMG-CoA reductase and increased enzymatic activity of lipase and LCAT.	atorvastatin	0-12	lecithin cholesterol acyltransferase	Rattus norvegicus	122-126
31674929-0	2019	Comparative effects of atorvastatin 80 mg and rosuvastatin 40 mg on the levels of serum endocan, chemerin, and galectin-3 in patients with acute myocardial infarction.	atorvastatin	23-35	endothelial cell specific molecule 1	Homo sapiens	88-95
31674929-6	2019	Chemerin levels significantly decreased in both groups according to baseline [from 264.90 (196.00-525.95) ng/mL to 135.00 (105.95-225.65) ng/mL with atorvastatin 80 mg and from 309.95 (168.87-701.27) ng/mL to 121.25 (86.60-212.65) ng/mL with rosuvastatin 40 mg, p<0.001, respectively, for both groups].	atorvastatin	149-161	retinoic acid receptor responder 2	Homo sapiens	0-8
31674929-2	2019	The aim of this study is to investigate and compare the effects of high doses of atorvastatin and rosuvastatin on serum endocan, chemerin, and galectin-3 levels in patients with acute myocardial infarction (AMI).	atorvastatin	81-93	endothelial cell specific molecule 1	Homo sapiens	120-127
31674929-7	2019	Galectin-3 levels did not change markedly with atorvastatin 80 mg, but they decreased with rosuvastatin 40 mg [from 17.00 (13.10-22.25) ng/mL to 19.30 (15.25-23.45) ng/mL with atorvastatin 80 mg, p=0.721, and from 18.25 (12.82-23.82) ng/mL to 16.60 (10.60-20.15) ng/mL with rosuvastatin 40 mg, p=0.074].	atorvastatin	176-188	galectin 3	Homo sapiens	0-10
31674929-2	2019	The aim of this study is to investigate and compare the effects of high doses of atorvastatin and rosuvastatin on serum endocan, chemerin, and galectin-3 levels in patients with acute myocardial infarction (AMI).	atorvastatin	81-93	galectin 3	Homo sapiens	143-153
31595197-13	2019	Atorvastatin treatment significantly decreased the levels of interleukins (IL-6 and IL-8) and tumor necrosis factor-alpha (TNF-alpha), but increased IL-10 level in the hematoma border.	atorvastatin	0-12	interleukin 10	Rattus norvegicus	149-154
31649888-4	2019	Atorvastatin also induced apoptosis in both cell lines, in which the reactive oxygen species (ROS)-related mitochondrial apoptotic signaling might be involved, with increase of ROS and Bax/Bcl-2 ratio, loss of mitochondrial membrane potential (MMP), release of cytochrome C into cytosol, and activation of Bax/Caspase-9/Caspase-3/PARP pathway.	atorvastatin	0-12	BCL2 associated X, apoptosis regulator	Homo sapiens	306-309
31649888-4	2019	Atorvastatin also induced apoptosis in both cell lines, in which the reactive oxygen species (ROS)-related mitochondrial apoptotic signaling might be involved, with increase of ROS and Bax/Bcl-2 ratio, loss of mitochondrial membrane potential (MMP), release of cytochrome C into cytosol, and activation of Bax/Caspase-9/Caspase-3/PARP pathway.	atorvastatin	0-12	caspase 9	Homo sapiens	310-319
31649888-4	2019	Atorvastatin also induced apoptosis in both cell lines, in which the reactive oxygen species (ROS)-related mitochondrial apoptotic signaling might be involved, with increase of ROS and Bax/Bcl-2 ratio, loss of mitochondrial membrane potential (MMP), release of cytochrome C into cytosol, and activation of Bax/Caspase-9/Caspase-3/PARP pathway.	atorvastatin	0-12	caspase 3	Homo sapiens	320-329
31649888-4	2019	Atorvastatin also induced apoptosis in both cell lines, in which the reactive oxygen species (ROS)-related mitochondrial apoptotic signaling might be involved, with increase of ROS and Bax/Bcl-2 ratio, loss of mitochondrial membrane potential (MMP), release of cytochrome C into cytosol, and activation of Bax/Caspase-9/Caspase-3/PARP pathway.	atorvastatin	0-12	collagen type XI alpha 2 chain	Homo sapiens	330-334
31649888-5	2019	Inhibition of YAP nuclear localization and activation by Atorvastatin was reversed by the addition of mevalonate, GGPP, or FPP.	atorvastatin	57-69	Yes1 associated transcriptional regulator	Homo sapiens	14-17
31649888-6	2019	Further, the effects on cell cycle arrest- and apoptosis- related proteins by Atorvastatin were alleviated by addition of mevalonate, suggesting the antileukemia effect of Atorvastatin might be through mevalonate-YAP axis in K562 and HL60 cells.	atorvastatin	78-90	Yes1 associated transcriptional regulator	Homo sapiens	213-216
31649888-6	2019	Further, the effects on cell cycle arrest- and apoptosis- related proteins by Atorvastatin were alleviated by addition of mevalonate, suggesting the antileukemia effect of Atorvastatin might be through mevalonate-YAP axis in K562 and HL60 cells.	atorvastatin	172-184	Yes1 associated transcriptional regulator	Homo sapiens	213-216
31595197-13	2019	Atorvastatin treatment significantly decreased the levels of interleukins (IL-6 and IL-8) and tumor necrosis factor-alpha (TNF-alpha), but increased IL-10 level in the hematoma border.	atorvastatin	0-12	interleukin 6	Rattus norvegicus	75-79
31595197-13	2019	Atorvastatin treatment significantly decreased the levels of interleukins (IL-6 and IL-8) and tumor necrosis factor-alpha (TNF-alpha), but increased IL-10 level in the hematoma border.	atorvastatin	0-12	tumor necrosis factor	Rattus norvegicus	94-121
31595197-13	2019	Atorvastatin treatment significantly decreased the levels of interleukins (IL-6 and IL-8) and tumor necrosis factor-alpha (TNF-alpha), but increased IL-10 level in the hematoma border.	atorvastatin	0-12	tumor necrosis factor	Rattus norvegicus	123-132
31649888-0	2019	Atorvastatin Exerts Antileukemia Activity via Inhibiting Mevalonate-YAP Axis in K562 and HL60 Cells.	atorvastatin	0-12	Yes1 associated transcriptional regulator	Homo sapiens	68-71
31649888-2	2019	The antileukemia activity of Atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, on human leukemia cells was investigated.	atorvastatin	29-41	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	45-102
31649888-3	2019	Atorvastatin inhibited K562 and HL60 cell proliferation, induced G2/M cell cycle arrest in K562 cells by down-regulating cyclinB1 and cdc2, but G0/G1 arrest in HL60 cells by up-regulating p27 and down-regulating cyclinD1 and p-pRb.	atorvastatin	0-12	cyclin B1	Homo sapiens	121-129
31649888-3	2019	Atorvastatin inhibited K562 and HL60 cell proliferation, induced G2/M cell cycle arrest in K562 cells by down-regulating cyclinB1 and cdc2, but G0/G1 arrest in HL60 cells by up-regulating p27 and down-regulating cyclinD1 and p-pRb.	atorvastatin	0-12	cyclin dependent kinase 1	Homo sapiens	134-138
31649888-3	2019	Atorvastatin inhibited K562 and HL60 cell proliferation, induced G2/M cell cycle arrest in K562 cells by down-regulating cyclinB1 and cdc2, but G0/G1 arrest in HL60 cells by up-regulating p27 and down-regulating cyclinD1 and p-pRb.	atorvastatin	0-12	interferon alpha inducible protein 27	Homo sapiens	188-191
31649888-3	2019	Atorvastatin inhibited K562 and HL60 cell proliferation, induced G2/M cell cycle arrest in K562 cells by down-regulating cyclinB1 and cdc2, but G0/G1 arrest in HL60 cells by up-regulating p27 and down-regulating cyclinD1 and p-pRb.	atorvastatin	0-12	cyclin D1	Homo sapiens	212-220
31649888-4	2019	Atorvastatin also induced apoptosis in both cell lines, in which the reactive oxygen species (ROS)-related mitochondrial apoptotic signaling might be involved, with increase of ROS and Bax/Bcl-2 ratio, loss of mitochondrial membrane potential (MMP), release of cytochrome C into cytosol, and activation of Bax/Caspase-9/Caspase-3/PARP pathway.	atorvastatin	0-12	BCL2 associated X, apoptosis regulator	Homo sapiens	185-188
31649888-4	2019	Atorvastatin also induced apoptosis in both cell lines, in which the reactive oxygen species (ROS)-related mitochondrial apoptotic signaling might be involved, with increase of ROS and Bax/Bcl-2 ratio, loss of mitochondrial membrane potential (MMP), release of cytochrome C into cytosol, and activation of Bax/Caspase-9/Caspase-3/PARP pathway.	atorvastatin	0-12	BCL2 apoptosis regulator	Homo sapiens	189-194
31649888-4	2019	Atorvastatin also induced apoptosis in both cell lines, in which the reactive oxygen species (ROS)-related mitochondrial apoptotic signaling might be involved, with increase of ROS and Bax/Bcl-2 ratio, loss of mitochondrial membrane potential (MMP), release of cytochrome C into cytosol, and activation of Bax/Caspase-9/Caspase-3/PARP pathway.	atorvastatin	0-12	cytochrome c, somatic	Homo sapiens	261-273
31894032-4	2019	Compared with the ischemia-reperfusion group, the MDA (16.23+-4.05), TNF alpha (41.84 +-5.61) and MPO (17.54+-2.81) were decreased in atorvastatin group.	atorvastatin	134-146	tumor necrosis factor	Rattus norvegicus	69-78
31574980-0	2019	CNOT2 Is Critically Involved in Atorvastatin Induced Apoptotic and Autophagic Cell Death in Non-Small Cell Lung Cancers.	atorvastatin	32-44	CCR4-NOT transcription complex subunit 2	Homo sapiens	0-5
31574980-3	2019	Atorvastatin increased cytotoxicity, sub G1 population, the number of apoptotic bodies, cleaved poly (ADP-ribose) polymerase (PARP) and caspase 3 and activated p53 in H1299, H596, and H460 cells.	atorvastatin	0-12	poly(ADP-ribose) polymerase 1	Homo sapiens	96-124
31574980-3	2019	Atorvastatin increased cytotoxicity, sub G1 population, the number of apoptotic bodies, cleaved poly (ADP-ribose) polymerase (PARP) and caspase 3 and activated p53 in H1299, H596, and H460 cells.	atorvastatin	0-12	poly(ADP-ribose) polymerase 1	Homo sapiens	126-130
31574980-3	2019	Atorvastatin increased cytotoxicity, sub G1 population, the number of apoptotic bodies, cleaved poly (ADP-ribose) polymerase (PARP) and caspase 3 and activated p53 in H1299, H596, and H460 cells.	atorvastatin	0-12	caspase 3	Homo sapiens	136-145
31574980-3	2019	Atorvastatin increased cytotoxicity, sub G1 population, the number of apoptotic bodies, cleaved poly (ADP-ribose) polymerase (PARP) and caspase 3 and activated p53 in H1299, H596, and H460 cells.	atorvastatin	0-12	tumor protein p53	Homo sapiens	160-163
31574980-4	2019	Notably, Atorvastatin inhibited the expression of c-Myc and induced ribosomal protein L5 and L11, but depletion of L5 reduced PARP cleavages induced by Atorvastatin rather than L11 in H1299 cells.	atorvastatin	9-21	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	50-55
31574980-4	2019	Notably, Atorvastatin inhibited the expression of c-Myc and induced ribosomal protein L5 and L11, but depletion of L5 reduced PARP cleavages induced by Atorvastatin rather than L11 in H1299 cells.	atorvastatin	9-21	ribosomal protein L5	Homo sapiens	68-88
31574980-4	2019	Notably, Atorvastatin inhibited the expression of c-Myc and induced ribosomal protein L5 and L11, but depletion of L5 reduced PARP cleavages induced by Atorvastatin rather than L11 in H1299 cells.	atorvastatin	152-164	poly(ADP-ribose) polymerase 1	Homo sapiens	126-130
31574980-5	2019	Also, Atorvastatin increased autophagy microtubule-associated protein 1A/1B-light chain 3II (LC3 II) conversion, p62/sequestosome 1 (SQSTM1) accumulation with increased number of LC3II puncta in H1299 cells.	atorvastatin	6-18	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	93-96
31574980-5	2019	Also, Atorvastatin increased autophagy microtubule-associated protein 1A/1B-light chain 3II (LC3 II) conversion, p62/sequestosome 1 (SQSTM1) accumulation with increased number of LC3II puncta in H1299 cells.	atorvastatin	6-18	sequestosome 1	Homo sapiens	113-131
31574980-5	2019	Also, Atorvastatin increased autophagy microtubule-associated protein 1A/1B-light chain 3II (LC3 II) conversion, p62/sequestosome 1 (SQSTM1) accumulation with increased number of LC3II puncta in H1299 cells.	atorvastatin	6-18	sequestosome 1	Homo sapiens	133-139
31574980-7	2019	Furthermore, autophagic flux assay using RFP-GFP-LC3 constructs and Lysotracker Red or acridine orange-staining demonstrated that autophagosome-lysosome fusion is blocked by Atorvastatin treatment in H1299 cells.	atorvastatin	174-186	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	49-52
31574980-8	2019	Conversely, overexpression of CCR4-NOT transcription complex subunit 2(CNOT2) weakly reversed the ability of Atorvastatin to increase cytotoxicity, sub G1 population, cleavages of PARP and caspase 3, LC3II conversion and p62/SQSTM1 accumulation in H1299 cells.	atorvastatin	109-121	CCR4-NOT transcription complex subunit 2	Homo sapiens	30-70
31574980-8	2019	Conversely, overexpression of CCR4-NOT transcription complex subunit 2(CNOT2) weakly reversed the ability of Atorvastatin to increase cytotoxicity, sub G1 population, cleavages of PARP and caspase 3, LC3II conversion and p62/SQSTM1 accumulation in H1299 cells.	atorvastatin	109-121	CCR4-NOT transcription complex subunit 2	Homo sapiens	71-76
31574980-8	2019	Conversely, overexpression of CCR4-NOT transcription complex subunit 2(CNOT2) weakly reversed the ability of Atorvastatin to increase cytotoxicity, sub G1 population, cleavages of PARP and caspase 3, LC3II conversion and p62/SQSTM1 accumulation in H1299 cells.	atorvastatin	109-121	poly(ADP-ribose) polymerase 1	Homo sapiens	180-184
31574980-8	2019	Conversely, overexpression of CCR4-NOT transcription complex subunit 2(CNOT2) weakly reversed the ability of Atorvastatin to increase cytotoxicity, sub G1 population, cleavages of PARP and caspase 3, LC3II conversion and p62/SQSTM1 accumulation in H1299 cells.	atorvastatin	109-121	caspase 3	Homo sapiens	189-198
31574980-8	2019	Conversely, overexpression of CCR4-NOT transcription complex subunit 2(CNOT2) weakly reversed the ability of Atorvastatin to increase cytotoxicity, sub G1 population, cleavages of PARP and caspase 3, LC3II conversion and p62/SQSTM1 accumulation in H1299 cells.	atorvastatin	109-121	sequestosome 1	Homo sapiens	221-224
31574980-8	2019	Conversely, overexpression of CCR4-NOT transcription complex subunit 2(CNOT2) weakly reversed the ability of Atorvastatin to increase cytotoxicity, sub G1 population, cleavages of PARP and caspase 3, LC3II conversion and p62/SQSTM1 accumulation in H1299 cells.	atorvastatin	109-121	sequestosome 1	Homo sapiens	225-231
31574980-9	2019	In contrast, CNOT2 depletion enhanced cleavages of PARP and caspase 3, LC3 conversion and p62/SQSTM1 accumulation in Atorvastatin treated H1299 cells.	atorvastatin	117-129	CCR4-NOT transcription complex subunit 2	Homo sapiens	13-18
31574980-9	2019	In contrast, CNOT2 depletion enhanced cleavages of PARP and caspase 3, LC3 conversion and p62/SQSTM1 accumulation in Atorvastatin treated H1299 cells.	atorvastatin	117-129	poly(ADP-ribose) polymerase 1	Homo sapiens	51-55
31574980-9	2019	In contrast, CNOT2 depletion enhanced cleavages of PARP and caspase 3, LC3 conversion and p62/SQSTM1 accumulation in Atorvastatin treated H1299 cells.	atorvastatin	117-129	caspase 3	Homo sapiens	60-69
31574980-9	2019	In contrast, CNOT2 depletion enhanced cleavages of PARP and caspase 3, LC3 conversion and p62/SQSTM1 accumulation in Atorvastatin treated H1299 cells.	atorvastatin	117-129	sequestosome 1	Homo sapiens	90-93
31574980-9	2019	In contrast, CNOT2 depletion enhanced cleavages of PARP and caspase 3, LC3 conversion and p62/SQSTM1 accumulation in Atorvastatin treated H1299 cells.	atorvastatin	117-129	sequestosome 1	Homo sapiens	94-100
31574980-10	2019	Overall, these findings suggest that CNOT2 signaling is critically involved in Atorvastatin induced apoptotic and autophagic cell death in NSCLCs.	atorvastatin	79-91	CCR4-NOT transcription complex subunit 2	Homo sapiens	37-42
31894032-5	2019	The results showed that atorvastatin could improve many hemodynamic indexes including SBP, DBP, LVSP, LVEDP and so on.	atorvastatin	24-36	spermine binding protein	Rattus norvegicus	86-89
31894032-5	2019	The results showed that atorvastatin could improve many hemodynamic indexes including SBP, DBP, LVSP, LVEDP and so on.	atorvastatin	24-36	D-box binding PAR bZIP transcription factor	Rattus norvegicus	91-94
31663350-8	2019	RESULTS: Co-treatment of atorvastatin + tamoxifen could strongly enhance the expression of pro/apoptotic factors of Bax and cytochrome c in melanoma cells compared to the tamoxifen and atorvastatin groups.	atorvastatin	25-37	BCL2-associated X protein	Mus musculus	116-119
31663350-9	2019	CONCLUSION: In general, we conclude that the atorvastatin-induced increase in Bax and cytochrome c gene expression might be a permissive response to tamoxifen-induced cell death (Fig.	atorvastatin	45-57	BCL2-associated X protein	Mus musculus	78-81
31933887-0	2019	The attenuation of myocardial hypertrophy by atorvastatin via the intracellular calcium signal and the p38 MAPK pathway.	atorvastatin	45-57	mitogen-activated protein kinase 14	Homo sapiens	103-106
31933887-3	2019	This study aimed to illustrate the effects of atorvastatin on Ang II-induced cardiac hypertrophy and to reveal its mechanism.	atorvastatin	46-58	angiogenin	Homo sapiens	62-65
31933887-5	2019	Then we determined whether atorvastatin could reverse cardiac hypertrophy markers and several cellular responses induced by Ang II to normal levels.	atorvastatin	27-39	angiogenin	Homo sapiens	124-127
31933887-9	2019	The activation of the p38 MAPK signaling pathway induced by Ang II was well inhibited by atorvastatin.	atorvastatin	89-101	mitogen-activated protein kinase 14	Homo sapiens	22-25
31933887-9	2019	The activation of the p38 MAPK signaling pathway induced by Ang II was well inhibited by atorvastatin.	atorvastatin	89-101	angiogenin	Homo sapiens	60-63
31933887-11	2019	CONCLUSION: Atorvastatin can attenuate cardiac hypertrophy induced by Ang II via the intracellular calcium signal and the p38 MAPK pathway.	atorvastatin	12-24	angiogenin	Homo sapiens	70-73
31933887-11	2019	CONCLUSION: Atorvastatin can attenuate cardiac hypertrophy induced by Ang II via the intracellular calcium signal and the p38 MAPK pathway.	atorvastatin	12-24	mitogen-activated protein kinase 14	Homo sapiens	122-125
31706904-3	2019	OBJECTIVES: The objectives of the study were to describe the treatment changes and low-density lipoprotein cholesterol (LDL-C) goal achievement with atorvastatin (ATV) and rosuvastatin (RV) in the SAFEHEART cohort, as well as to analyze the incidence of atherosclerotic cardiovascular events (ACVEs) and changes in the cardiovascular risk.	atorvastatin	149-161	component of oligomeric golgi complex 2	Homo sapiens	83-118
31706904-3	2019	OBJECTIVES: The objectives of the study were to describe the treatment changes and low-density lipoprotein cholesterol (LDL-C) goal achievement with atorvastatin (ATV) and rosuvastatin (RV) in the SAFEHEART cohort, as well as to analyze the incidence of atherosclerotic cardiovascular events (ACVEs) and changes in the cardiovascular risk.	atorvastatin	149-161	component of oligomeric golgi complex 2	Homo sapiens	120-125
31706904-3	2019	OBJECTIVES: The objectives of the study were to describe the treatment changes and low-density lipoprotein cholesterol (LDL-C) goal achievement with atorvastatin (ATV) and rosuvastatin (RV) in the SAFEHEART cohort, as well as to analyze the incidence of atherosclerotic cardiovascular events (ACVEs) and changes in the cardiovascular risk.	atorvastatin	163-166	component of oligomeric golgi complex 2	Homo sapiens	83-118
31706904-10	2019	Sixteen percent of patients in primary prevention with ATV and 18% with RV achieved an LDL-C <100 mg/dL and 4% in secondary prevention with ATV and 5% with RV achieved an LDL-C <70 mg/dL.	atorvastatin	55-58	component of oligomeric golgi complex 2	Homo sapiens	87-92
31706904-14	2019	Although the reduction in LDL-C levels was greater with RV than with ATV, the superiority of RV for reducing ACVEs was not demonstrated.	atorvastatin	69-72	component of oligomeric golgi complex 2	Homo sapiens	26-31
31966465-0	2017	DNAH11 rs12670798 variant and G x E interactions on serum lipid levels, coronary heart disease, ischemic stroke and the lipid-lowering efficacy of atorvastatin.	atorvastatin	147-159	dynein axonemal heavy chain 11	Homo sapiens	0-6
31846093-0	2020	Effect of atorvastatin on Abeta1-42 -induced alteration of SESN2, SIRT1, LC3II and TPP1 protein expressions in neuronal cell cultures.	atorvastatin	10-22	sestrin 2	Homo sapiens	59-64
31846093-0	2020	Effect of atorvastatin on Abeta1-42 -induced alteration of SESN2, SIRT1, LC3II and TPP1 protein expressions in neuronal cell cultures.	atorvastatin	10-22	sirtuin 1	Homo sapiens	66-71
31846093-0	2020	Effect of atorvastatin on Abeta1-42 -induced alteration of SESN2, SIRT1, LC3II and TPP1 protein expressions in neuronal cell cultures.	atorvastatin	10-22	tripeptidyl peptidase 1	Homo sapiens	83-87
31846093-3	2020	METHODS: This study was undertaken whether Abeta-induced changes of SESN2 and SIRT1 protein expression, autophagy marker LC3II and lysosomal enzyme TPP1 affected by atorvastatin (Western blot) and its possible role in Abeta neurotoxicity (ELISA).	atorvastatin	165-177	sirtuin 1	Homo sapiens	78-83
31846093-5	2020	Co-administration of atorvastatin with Abeta1-42 compensates SESN2 increase and recovers SIRT1 decline by reducing oxidative stress, decreasing SESN2 expression and increasing SIRT1 expression by its neuroprotective action.	atorvastatin	21-33	sestrin 2	Homo sapiens	61-66
31846093-5	2020	Co-administration of atorvastatin with Abeta1-42 compensates SESN2 increase and recovers SIRT1 decline by reducing oxidative stress, decreasing SESN2 expression and increasing SIRT1 expression by its neuroprotective action.	atorvastatin	21-33	sirtuin 1	Homo sapiens	89-94
31846093-5	2020	Co-administration of atorvastatin with Abeta1-42 compensates SESN2 increase and recovers SIRT1 decline by reducing oxidative stress, decreasing SESN2 expression and increasing SIRT1 expression by its neuroprotective action.	atorvastatin	21-33	sestrin 2	Homo sapiens	144-149
31846093-5	2020	Co-administration of atorvastatin with Abeta1-42 compensates SESN2 increase and recovers SIRT1 decline by reducing oxidative stress, decreasing SESN2 expression and increasing SIRT1 expression by its neuroprotective action.	atorvastatin	21-33	sirtuin 1	Homo sapiens	176-181
31846093-7	2020	DISCUSSION AND CONCLUSION: Together, these results indicate that atorvastatin induced SESN2, SIRT1 and LC3II levels play a protective role against Abeta1-42 neurotoxicity.	atorvastatin	65-77	sestrin 2	Homo sapiens	86-91
31846093-7	2020	DISCUSSION AND CONCLUSION: Together, these results indicate that atorvastatin induced SESN2, SIRT1 and LC3II levels play a protective role against Abeta1-42 neurotoxicity.	atorvastatin	65-77	sirtuin 1	Homo sapiens	93-98